Skip to content
Boca Raton City Online – Lifestyle
Author:
Lexaria Bioscience Corp.
Lexaria Announces Results from Animal Study GLP-1-A26-1
October 15, 2026
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
October 6, 2026
Lexaria Updates Financial Position
September 17, 2026
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 9, 2026
Lexaria Bioscience Exercises Warrants for $5.9M
September 8, 2026
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 4, 2026
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 1, 2026
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2
August 24, 2026
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
1
2
3
Next Page
→